Biotechnology / Biopharmaceuticals - Oncology and Immunotherapy
Strategic Profile
The company has strategic partnerships with major pharma including Merck Sharp & Dohme, Eli Lilly, Bristol-Myers Squibb, GlaxoSmithKline, Daiichi Sankyo, Janssen Biotech, BeiGene, and Exelixis. Lead product zanidatamab is in Phase 1, Phase 2, and Phase 3 clinical trials, with zanidatamab zovodotin in Phase 2 trials for advanced HER2-expressing tumors.
Cyborg Score Rationale
While Zymeworks has strong biotech platform capabilities and major pharma partnerships, the company is still clinical-stage with negative EBITDA and burn rate concerns. Recent management restructuring and employee count reduction signal financial pressures amid late-stage pipeline progress.
Top Insights
Proprietary platform portfolio includes Azymetric multispecific antibody platform, Drug Conjugate platform with cytotoxins, EFECT immune modulation platform, and ProTECT tumor-specific co-stimulation platform.
As of February 7, 2026, the company has 286 employees.
EBITDA is negative at -$57.82M with EBITDA margin of -142.36%, indicating significant operating losses.
Recent leadership changes include appointment of Brian Cherry to Board of Directors, Dr. Sabeen Mekan transition to Chief Medical Officer, Mark Hollywood promotion to Executive Vice President and COO, and five new Vice Presidents appointed (January 2026).
Named Competitors
Bispecific Antibodies — Develops bispecific antibodies for oncology and other therapeutic areas
Bispecific Antibodies — Leading provider of bispecific antibody platform technology
Antibody-Drug Conjugates — Develops ADCs for cancer treatment
Recent Developments
(January 2026) Leadership restructuring with new Board member, CMO transition, COO promotion, and five VP appointments
(February 2026) Dr. Sabeen Mekan officially transitioned to Chief Medical Officer role
(April 2017) IPO on Toronto Stock Exchange; later cross-listed on NASDAQ
Open the full interactive Zymeworks Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.